|
gptkbp:instanceOf
|
gptkb:drug
GLP-1 receptor agonist
|
|
gptkbp:activeIngredient
|
gptkb:semaglutide
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:A10BJ06
|
|
gptkbp:bioavailability
|
low (about 1%)
|
|
gptkbp:brand
|
gptkb:Rybelsus
|
|
gptkbp:coAdministeredWith
|
gptkb:sodium_N-(8-[2-hydroxybenzoyl]amino)caprylate_(SNAC)
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
|
|
gptkbp:developer
|
gptkb:Novo_Nordisk
|
|
gptkbp:effect
|
promotes weight loss
reduces blood glucose
|
|
gptkbp:eliminatedIn
|
urine and feces
|
|
gptkbp:form
|
gptkb:tablet
oral tablet
|
|
gptkbp:halfLife
|
about 1 week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oral semaglutide
|
|
gptkbp:indication
|
gptkb:type_2_diabetes
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor agonism
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRequired
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
decreased appetite
|
|
gptkbp:bfsParent
|
gptkb:Emisphere_Technologies
|
|
gptkbp:bfsLayer
|
7
|